Cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-08-01. Numbers and descriptions here follow the published literature rather than marketing material.
After subcutaneous administration, plasma concentrations rise within roughly thirty minutes and the elimination half-life is short, on the order of two to three hours. Reported physiological responses include transient increases in blood pressure and nausea, which tended to diminish with repeated dosing in trial settings. Because the peptide clears quickly, effects are not expected to persist long after a dose. Absorption from non-injected routes is poorly characterised, and nasal delivery produced variable plasma levels in older work.
Clinical research typically uses randomised, double-blind, placebo-controlled designs. The most common primary endpoint is the desire domain score of the Female Sexual Function Index, sometimes paired with a distress measure. Secondary outcomes include arousal, satisfaction, and event-based counts of satisfying sexual episodes. Across trials, average improvements are modest and individual responses vary widely. Whether benefits persist beyond a few months, and whether they depend on baseline hormone status, remain open questions rather than settled findings.
Melanocortin receptors form a family of five G-protein-coupled receptors designated MC1 through MC5. Bremelanotide binds most strongly at MC4R and MC1R, with weaker activity reported at MC3R and MC5R. MC4R is expressed in hypothalamic nuclei that coordinate energy balance and aspects of sexual behaviour. The prevailing interpretation is that central MC4R activation, rather than peripheral vascular effects alone, drives the reported changes in desire. This account remains partly inferential, since direct receptor-level measurement in living humans is not practical.
Handling procedures emphasize minimizing moisture uptake, since the dried solid is hygroscopic and can draw water when warmed to room temperature before a vial is opened. Laboratories record lot number, purity, counter-ion content, and residual solvent data supplied by the producer. Impurity profiles are compared run to run, and any shift in retention time or peak shape prompts re-verification against a reference standard. Certificates of analysis are treated as claims to be checked rather than accepted at face value.
Identity and purity testing for this peptide typically relies on reversed-phase high-performance liquid chromatography with ultraviolet detection, reported as area-percent purity. Mass spectrometry, usually in tandem mode, confirms molecular mass and supports quantification in biological matrices. Sequence confirmation may use peptide mapping after enzymatic digestion, while nuclear magnetic resonance and circular dichroism supply supplementary structural detail. No single technique establishes identity alone, so laboratories compare retention time, mass, and fragment pattern against a verified reference standard.
| Property | Value | Notes |
|---|---|---|
| Primary receptor targets | MC4R and MC1R | Agonist activity; MC3R and MC5R weaker |
| Route studied in trials | Subcutaneous injection | Intranasal form was not approved |
| Elimination half-life | Approximately 2–3 hours | Short relative to the dosing interval |
| Common analytical method | Liquid chromatography–tandem mass spectrometry | Used for peptide quantification in plasma |
| Reported adverse events | Nausea, flushing, headache | Transient blood pressure rise also noted |
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.
Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.
PT-141 is a synthetic cyclic heptapeptide whose development code is bremelanotide. It belongs to the class of melanocortin receptor agonists and acts by mimicking endogenous peptide hormones. The compound originated from research on melanotan II, where investigators exploring derivatives found distinct pharmacological features. Unlike the parent compound, PT-141 showed effects on pathways related to sexual desire and function in early studies, prompting its development as a separate candidate. Its molecular design aimed to separate receptor activity from pigmentary effects.
The molecular backbone consists of seven amino acid residues joined into a ring through a disulfide bridge. This cyclic conformation is critical for receptor binding. The sequence includes an acetylated N-terminus and an amidated C-terminus, modifications that improve resistance to enzymatic breakdown. One residue is in the D-configuration, a feature that further stabilizes the peptide against protease activity. Together, the ring structure and specific stereochemistry determine selectivity among melanocortin receptor subtypes.
== Melamine on metal surfaces == It is reported that melamine molecules adsorbed on gold or silver surface tend to arrange into honeycomb or closed-packed structures. Such a self-assembly occurs due to the inter-molecular hydrogen bond interaction. This ordering was further investigated using classical Monte Carlo and DFT methods.
== External links == GeneReviews/NCBI/NIH/UW entry on Aceruloplasminemia OMIM entries on Aceruloplasminemia Overview of all the structural information available in the PDB for UniProt: P00450 (Human Ceruloplasmin) at the PDBe-KB.
Nanohedron.com images of nanoparticles Lectures on All Phases of Nanoparticle Science and Technology Archived 29 August 2010 at the Wayback Machine ENPRA – Risk Assessment of Engineered NanoParticles EC FP7 Project led by the Institute of Occupational Medicine
The electrophoretic linear (horizontal) separation of proteins by Ip along a pH gradient in a polyacrylamide gel (also known as isoelectric focusing), followed by a standard molecular weight linear (vertical) separation in a second polyacrylamide gel (SDS-PAGE), constitutes the so called two-dimensional gel electrophoresis or PAGE 2D. This technique allows a thorough separation of proteins as distinct "spots", with proteins of high molecular weight and low Ip migrating to the upper-left part of the bidimensional gel, while proteins with low molecular weight and high Ip locate to the bottom-right region of the same gel.
pnictogen Any of the chemical elements belonging to Group (V) of the periodic table: nitrogen (N), phosphorus (P), arsenic (As), antimony (Sb), bismuth (Bi), and moscovium (Ms). These elements are united by their common pentavalency; i.e. in their non-ionized states, atoms of these elements all have exactly five valence electrons in their outermost electron shell, three short of a complete octet.
Sources: en.wikipedia.org
Christopher Columbus began exploring the Caribbean for Spain in 1492, leading to Spanish-speaking settlements and missions from what are now Puerto Rico and Florida to New Mexico and California. The first Spanish colony in the present-day continental United States was Spanish Florida, chartered in 1513. After several settlements failed there due to starvation and disease, Spain's first permanent town, Saint Augustine, was founded in 1565. France established its own settlements in French Florida in 1562, but they were either abandoned (Charlesfort, 1563) or destroyed by Spanish raids (Fort Caroline, 1565). Permanent French settlements were founded much later along the Great Lakes (Fort Detroit, 1701), the Mississippi River (St. Louis, 1764) and especially the Gulf of Mexico (New Orleans, 1718). Early European colonies also included the thriving Dutch colony of New Nederland (settled 1626, present-day New York) and the small Swedish colony of New Sweden (settled 1638 in what became Delaware). British colonization of the East Coast began with the Virginia Colony (1607) and the Plymouth Colony (Massachusetts, 1620). The Mayflower Compact in Massachusetts and the Fundamental Orders of Connecticut established precedents for local representative self-governance and constitutionalism that would develop throughout the American colonies. While European settlers in what is now the United States experienced conflicts with Native Americans, they also engaged in trade, exchanging European tools for food and animal pelts. Relations ranged from close cooperation to warfare and massacres.
Susan Weintraub is an American scientist. She is a professor at the University of Texas Health Science Center at San Antonio (UTHSCSA). She received a BS in chemistry from the University of Pennsylvania in 1967, MS in chemistry from Trinity University in 1970 and a PhD in biochemistry from UTHSCSA in 1979. She was the president of the American Society for Mass Spectrometry for the period of 2012-2014. In 2017 she was named a Fellow of the American Association for the Advancement of Science (AAAS), and Fellow of the American Society for Mass Spectrometry in 2025. She is an associate editor of the Journal of Proteome Research. Her research focuses on biomedical mass spectrometry where she used mass spectrometry in the early 1970s for quantitative analysis of brain neurochemicals. She has been director of the mass spectrometry core resource at UTHSCSA since 1979.
Known instances of nuclear reactions, aside from producing energy, also produce nucleons and particles on readily observable ballistic trajectories. In support of their claim that nuclear reactions took place in their electrolytic cells, Fleischmann and Pons reported a neutron flux of 4,000 neutrons per second, as well as detection of tritium. The classical branching ratio for previously known fusion reactions that produce tritium would predict, with 1 watt of power, the production of 1012 neutrons per second, levels that would have been fatal to the researchers. In 2009, Mosier-Boss et al. reported what they called the first scientific report of highly energetic neutrons, using CR-39 plastic radiation detectors, but the claims cannot be validated without a quantitative analysis of neutrons. Several medium and heavy elements like calcium, titanium, chromium, manganese, iron, cobalt, copper and zinc have been reported as detected by several researchers, like Tadahiko Mizuno or George Miley. The report presented to the United States Department of Energy (DOE) in 2004 indicated that deuterium-loaded foils could be used to detect fusion reaction products and, although the reviewers found the evidence presented to them as inconclusive, they indicated that those experiments did not use state-of-the-art techniques.
In the United States Code, the IEEPA is Title 50, §§1701–1707. The IEEPA authorizes the president to declare the existence of an "unusual and extraordinary threat ... to the national security, foreign policy, or economy of the United States" that originates "in whole or substantial part outside the United States." It further authorizes the president, after such a declaration, to block transactions and freeze assets to deal with the threat and requires the president to report to Congress every 6 months on the circumstances, threats and actions taken. In the event of an actual attack on the United States, the president can also confiscate property connected with a country, group, or person that aided in the attack. IEEPA falls under the provisions of the National Emergencies Act (NEA), which means that an emergency declared under the act must be renewed annually to remain in effect. The authority given to the president under the IEEPA does not grant him the ability to regulate or prohibit communication that "does not involve a transfer of anything of value", imports or exports of information or any informational materials, or transactions incidental to travel. Donations intended to relieve human suffering, such as food, clothing or medicine are also excluded unless the president specifically finds their inclusion necessary.
Sources: en.wikipedia.org
Trial results generally show a small to moderate average improvement in desire scores relative to placebo. The distribution of responses is wide, and some participants show little measurable change. Group averages should not be read as a prediction for any single person.
Nausea, flushing, headache, and transient blood pressure elevation are the most frequently reported events. These typically appear shortly after dosing and are usually described as mild to moderate in severity. Safety data covering long periods of continuous use remain limited.
A short half-life means the compound clears from circulation within hours, so any effect is tied closely to dosing time. Accumulation between doses is therefore unlikely under the studied schedule. The practical consequence is that timing of administration shapes what observers record.
Chemical degradation such as hydrolysis and oxidation proceeds more slowly as temperature falls. Cold storage also limits microbial growth in reconstituted material. Repeated warming should be avoided because thermal cycling stresses the peptide.